Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of LBL-024 plus platinum chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma
CTR20262802Phase 3Active
- Sponsor
- Leads Biolabs
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of opamtistomig in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Leads Biolabs. Started Jul 2026; status: active.
02
Drugs
opamtistomig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on CTR20262802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262802.